Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer.

Authors

Joelle Soriano

Joelle Soriano

Princess Margaret Cancer Center, Toronto, ON, Canada

Joelle Soriano , Katrina Hueniken , Jaspreet K. Bajwa , George Dong , Wanning Wang , Tyler Soberano , Kirsty Taylor , M. Catherine Brown , Eric Xueyu Chen , Jennifer J. Knox , Raymond Woo-Jun Jang , Rebecca Wong , Gail Elizabeth Darling , Wei Xu , Elena Elimova , Geoffrey Liu , Dmitry Rozenberg , Micheal McInnis , Aline Fusco Fares

Organizations

Princess Margaret Cancer Center, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, University of Toronto, Department of Medical Imaging, Toronto, ON, Canada, Joint Department of Medical Imaging (JDMI), Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada, University of Texas MD Anderson Cancer Center, Houston, TX, Toronto General Hospital, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada

Research Funding

No funding received
None

Background: Body fat and muscle influence prognosis in many cancer types. However, this association is unclear for real-world MEC pts, who are often in worse performance status than their previous baseline. In addition, the relationship of BM at presentation and QoL is unknown. We used real-world MEC pts to assess the importance of BM in OS and QoL. Methods: BM were done at baseline computed tomography in MEC pts, treated from 2006-2014 at the Princess Margaret Cancer Centre. Two radiologists (correlation 0.9-1.0) assessed L3 level using SliceOMatic to determine Skeletal Muscle Index (SMI - muscle area at L3 normalized by height), Visceral Adiposity Tissue (VAT), and Subcutaneous Adiposity Tissue (SAT). We used previously published cut-offs for sarcopenia based on sex and BMI, and the highest tertile as the cut-off for adiposity. We used prospectively collected QoL surveys including EuroQol 5D-5L (EQ5D) and the Functional Assessment of Cancer Therapy – Esophageal (FACT-E). Results: Of 200 pts, 164 (82%) were male, 180 (92%) were non-Asian; mean age was 62 y; ECOG: 0-1 = 142 (71%), 2 = 58 (29%); 69% had adenocarcinoma; 5% were underweight, 44% normal weight, 30% overweight, and 21% obese. 40 (20%) pts completed QoL measures. We found that 104 (52%) were sarcopenic at baseline, 66 (33%) had high VAT, and 67 (34%) had high SAT. A multivariable Cox model showed that sarcopenia and VAT were independent prognostic variables for three-year OS: sarcopenia increased the risk of death by 50% (adjusted hazard ratio, aHR 1.50, p 0.02), whereas every 100-cm2 increase in VAT improved OS by 24% (aHR 0.76, p 0.03). Finally, sarcopenic pts had significantly worse physical well-being (p 0.01) on FACT-E after adjusting for sex and age. Numerically, the EQ5D also showed lower scores in sarcopenic pts but this was not statistically significant (p 0.18). Conclusions: In MEC pts, sarcopenia and low visceral adiposity result in worse OS; sarcopenia is also significantly associated with poor QoL. Future work will need to focus on potential rehabilitation strategies such as nutritional support and exercise training to offset the poor prognosis associated with sarcopenia and reduced adiposity.

aHR (95% CI)P-value
Sarcopenic (ref: non-sarcopenic)1.50 (1.0-2.1)0.02
VAT (per 100cm2)0.97 (0.9-0.9)0.03
SAT (per 100cm2)1.01 (0.9-1.0)0.39
BMI < 18.5 (ref: 18.5-24.9)1.36 (0.6-2.8)0.41
BMI 25-29.9 (ref: 18.5-24.9)0.81 (0.5-1.2)0.35
BMI 30+ (ref: 18.5-24.9)1.28 (0.7-2.2)0.39

Cox model, OS adjusted for age, sex, ECOG, number of metastatic sites.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4544)

DOI

10.1200/JCO.2020.38.15_suppl.4544

Abstract #

4544

Poster Bd #

152

Abstract Disclosures

Similar Abstracts

First Author: Stefanie Zschaebitz

First Author: Senaka A. Peter